Transgene Aktie
| 0,59EUR | 0,00EUR | 0,34% |
WKN: 913048 / ISIN: FR0005175080
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 165 | 167 | 167 | 158 | 165 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,02 | 0,06 | 0,02 | 0,01 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 31 | 62 | 47 | 18 | 21 |
| Summe Anlagevermögen | 55 | 40 | 20 | 27 | 22 |
| Summe Aktiva | 85 | 102 | 66 | 45 | 42 |
Bilanz (in Mio. EUR) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 35 | 35 | 29 | 30 | 27 |
| Summe Eigenkapital | 50 | 67 | 38 | 16 | 15 |
| Summe Passiva | 85 | 102 | 66 | 45 | 42 |
Adresse
| 400, boulevard Gonthier d'Andernach, 67405 Strasbourg | |
| Telefon | +33 (3) 88-27-91-00 |
| Fax | +33 (3) 88-27-91-11 |
| Internet | http://www.transgene.fr |
Management
|
Alain Mérieux
Honorary Chairman |
|
Alessandro Riva
Chairman & Chief Executive Officer |
|
Benoît Habert
Independent Director |
|
Carol Stuckley
Independent Director |
|
Christelle Schwoerer
Chief Human Resources Officer |
|
Christophe Ancel
VP-Pharmaceutical Operations |
|
Emmanuelle Dochy
Chief Medical Officer |
|
James Wentworth
Chief Business Officer & Vice President |
|
Jean-Luc Bélingard
Director |
|
Jean-Yves Blay
Independent Director |
|
John Felitti
Secretary, Vice President & General Counsel |
|
Lucie Larguier
CFO, Director-Corporate Communications & IR |
|
Marie-Yvonne Landel-Meunier
Independent Director |
|
Maurizio Ceppi
Chief Scientific Officer |
|
Maya R. Said
Independent Director |
|
Michel Baguenault de Puchesse
Director |
|
Philippe Archinard
Director |
|
Sandrine Flory
Director |
|
Simone Steiner
Chief Technical Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.